This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview

This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

Expert Analysis of New Data From APLAR, EULAR, and JCR 2019

Expert Analysis of New Data From APLAR, EULAR, and JCR 2019

Format

Roundtable

Time to Complete

1 hour

Released

August 19, 2019

Expires

August 19, 2020
Add to Queue


Maximum Credits

1.00 / AMA PRA Category 1 Credit(s)TM

Accredited Provider

Provided by the Annenberg Center for Health Sciences at Eisenhower

Commercial Supporter

Supported by educational grants from Gilead Sciences, Lilly, and Sanofi Genzyme and Regeneron Pharmaceuticals.

Program Description

This expert-led CME-certified activity provides a comprehensive review of key rheumatoid arthritis data from EULAR* and more, including:

  • Can we safely taper corticosteroids after treatment with biologic DMARDs?
  • Should we attempt to withdraw MTX after treatment with biologic DMARDs or JAK inhibitors?
  • What are the clinical implications of the latest data on new and emerging JAK inhibitors?
  • What does the future hold for investigational small molecule inhibitors?

Intended Audience

This program is intended for physicians and other healthcare providers who care for patients with RA.

Educational Objectives

Upon completion of this activity, participants should be able to:

  • Identify key findings from real-world experience in the management of TNF inhibitor–refractory patients with RA
  • Describe outcomes from RA studies of biologic and targeted DMARD therapy initiated early in the disease course
  • Summarize clinical trial results and potential applications of emerging therapies for RA

Conflict Of Interest Disclosure Policy

The Annenberg Center assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME/CE activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty

Stanley B. Cohen, MD
Clinical Professor
Department of Internal Medicine
University of Texas Southwestern Medical School
Co-Director
Division of Rheumatology
Presbyterian Hospital
Co-Medical Director
Metroplex Clinical Research Center
Dallas, Texas

Dr. Cohen has disclosed that he has received consulting fees and funds for research support from AbbVie, Amgen, Gilead Sciences, Lilly, and Pfizer.

Jonathan Kay, MD
Professor of Medicine and Population & Quantitative Health Sciences
Timothy S. and Elaine L. Peterson Chair in Rheumatology

Division of Rheumatology
Department of Medicine
University of Massachusetts Medical School
Physician
Division of Rheumatology
Department of Medicine
UMass Memorial Medical Center
Worcester, Massachusetts

Dr. Kay has disclosed that he has he has received consulting fees from AbbVie, Boehringer Ingelheim, Celltrion, Horizon, Kolon TissueGene, Merck Sharp and Dohme, MorphoSys, Novartis, Pfizer, Roche, Samsung Bioepis, Sandoz, and Union Chimique Belge and funds for research support from Gilead Sciences, Pfizer, and Union Chimique Belge.

Accredited Provider Disclosures

Charles E. Willis, Director of Continuing Education; Amanda Sewell, MBA, Manager of Continuing Education and Melissa Velasquez, Accreditation Specialist from the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

Publishing Staff Disclosures

Zachary Schwartz, MSc, Carolyn Skoronski, PharmD and Tiffany Hensley-McBain, PhD of Clinical Care Options have no relevant conflicts of interest to report. Joy Curzio has disclosed that she has ownership interests in Advaxis, Editas and OnoSec.

The PIM planners and managers have nothing to disclose.

Credit

1.00

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation Statement

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.00 AMA PRA Category 1 CreditTM .  Physicians should claim only the credit commensurate with the extent of their participation in the activity

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Annenberg Center, Postgraduate Institute for Medicine (PIM), Clinical Care Options, and activity supporters do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Annenberg Center, PIM, Clinical Care Options, and activity supporters. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Instructions

To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate.

Your online certificate will be saved and accessible on the Clinical Care Options website and will not be saved to your myCME CME History.

If you have any questions relating to the accreditation of this activity, please contact customersupport@clinicaloptions.com.
Add to Queue